Join the Osteoporosis group to help and get support from people like you.
Osteoporosis News (Page 2)
Related terms: Bone Thinning
Common Tools Suboptimal for ID'ing Fracture Risk in Younger Postmenopausal Women
MONDAY, June 12, 2023 – The Fracture Risk Assessment Tool (FRAX) and the Osteoporosis Self-assessment Tool (OST) have suboptimal performance for predicting 10-year major osteoporotic fracture risk...
Femoral Neck BMD Lower in Men With Combat-Related Traumatic Injury
THURSDAY, May 18, 2023 – Individuals with combat-related traumatic injury (CRTI) have lower femoral neck bone mineral density (BMD), with this reduction significant only at the femoral neck of the...
Bone Up on Osteoporosis & Your Bone Health
MONDAY, May 15, 2023 – It’s important to understand your bone health to avoid damage as you age. Losses of bone mineral density and bone mass can cause weakening, potentially leading to a fracture, e...
Hormone Preparations Tied to Increased Bone Mineral Density in Postmenopausal Women
THURSDAY, May 11, 2023 – Hormone preparations are associated with an increase in lumbar spine bone mineral density (BMD) in postmenopausal women, according to a study published online May 2 in...
Radius Health’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Cambridge, Mass., December 20, 2022 – Radius Health, Inc. (“Radius” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos® (abaloparatide), a parathy...
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for Bonsity (PF708) submi...
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
April 9, 2019 – The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are...
FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment...
FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
WALTHAM, Mass., April 28, 2017 (GLOBE NEWSWIRE) – Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing innovative...
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle
Miami, FL and New York, NY, – September 24, 2014 – Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...
FDA Approves Binosto, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
FREIENBACH, Switzerland, March 14, 2012 /PRNewswire/ – EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved Binosto (alendronate sodium)...
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel
ARDEE, Ireland, October 11, 2010 /PRNewswire-FirstCall/ – Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation Actonel...
FDA Approves Amgen's Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia (denosumab) for the treatment of...
Ask a question
To post your own question to this support group, sign in or create an account.